299 related articles for article (PubMed ID: 24167124)
1. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
[TBL] [Abstract][Full Text] [Related]
2. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
Alshamsan A; Hamdy S; Samuel J; El-Kadi AO; Lavasanifar A; Uludağ H
Biomaterials; 2010 Feb; 31(6):1420-8. PubMed ID: 19913908
[TBL] [Abstract][Full Text] [Related]
3. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response.
Alshamsan A; Haddadi A; Hamdy S; Samuel J; El-Kadi AO; Uludağ H; Lavasanifar A
Mol Pharm; 2010 Oct; 7(5):1643-54. PubMed ID: 20804176
[TBL] [Abstract][Full Text] [Related]
4. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
[TBL] [Abstract][Full Text] [Related]
5. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells.
Su WP; Cheng FY; Shieh DB; Yeh CS; Su WC
Int J Nanomedicine; 2012; 7():4269-83. PubMed ID: 22904633
[TBL] [Abstract][Full Text] [Related]
6. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo.
Das J; Das S; Paul A; Samadder A; Bhattacharyya SS; Khuda-Bukhsh AR
Toxicol Lett; 2014 Mar; 225(3):454-66. PubMed ID: 24440344
[TBL] [Abstract][Full Text] [Related]
7. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice.
Yang Z; Cai JH; Xie SJ; Li GX; Song WQ; Yan QH; Yan L; Zhang F
Chin Med J (Engl); 2011 Jun; 124(12):1854-61. PubMed ID: 21740845
[TBL] [Abstract][Full Text] [Related]
9. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
10. Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3.
Yang MY; Wang CJ; Chen NF; Ho WH; Lu FJ; Tseng TH
Chem Biol Interact; 2014 Apr; 213():60-8. PubMed ID: 24525192
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression.
Huang HY; Kuo WT; Chou MJ; Huang YY
J Biomed Mater Res A; 2011 Jun; 97(3):330-8. PubMed ID: 21465641
[TBL] [Abstract][Full Text] [Related]
12. Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.
Aliabadi HM; Maranchuk R; Kucharski C; Mahdipoor P; Hugh J; Uludağ H
J Control Release; 2013 Nov; 172(1):219-228. PubMed ID: 23994345
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells.
Lu S; Morris VB; Labhasetwar V
J Pharmacol Exp Ther; 2019 Sep; 370(3):902-910. PubMed ID: 30940690
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
[TBL] [Abstract][Full Text] [Related]
15. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.
Gariboldi MB; Ravizza R; Molteni R; Osella D; Gabano E; Monti E
Cancer Lett; 2007 Dec; 258(2):181-8. PubMed ID: 17920763
[TBL] [Abstract][Full Text] [Related]
17. Functional graphene oxide as a plasmid-based Stat3 siRNA carrier inhibits mouse malignant melanoma growth in vivo.
Yin D; Li Y; Lin H; Guo B; Du Y; Li X; Jia H; Zhao X; Tang J; Zhang L
Nanotechnology; 2013 Mar; 24(10):105102. PubMed ID: 23425941
[TBL] [Abstract][Full Text] [Related]
18. Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early- and Late-Stage Metastatic Breast Cancer.
Chen G; Wang Y; Wu P; Zhou Y; Yu F; Zhu C; Li Z; Hang Y; Wang K; Li J; Sun M; Oupicky D
ACS Nano; 2018 Jul; 12(7):6620-6636. PubMed ID: 29985577
[TBL] [Abstract][Full Text] [Related]
19. siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers.
Sahin B; Fife J; Parmar MB; Valencia-Serna J; Gul-Uludağ H; Jiang X; Weinfeld M; Lavasanifar A; Uludağ H
Biomaterials; 2014 Nov; 35(34):9382-94. PubMed ID: 25128374
[TBL] [Abstract][Full Text] [Related]
20. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
